Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses

Cancer Biology and Therapy

Volumn 14, Issue 5, 2013, Pages 411-416

  Galvin, John P ^a   Altman, Jessica K ^a,b   Szilard, Amy ^a   Goussetis, Dennis J ^a,b   Vakana, Eliza ^a   Sassano, Antonella ^a   Platanias, Leonidas C ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Acute myeloid leukemia; Arsenic trioxide; Kinase; RSK1

Indexed keywords

ARSENIC TRIOXIDE; S6 KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; HUMAN CELL; NEGATIVE FEEDBACK; SIGNAL TRANSDUCTION;

ACUTE MYELOID LEUKEMIA; ARSENIC TRIOXIDE; KINASE; RSK1;

APOPTOSIS; ARSENICALS; CELL LINE, TUMOR; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; LEUKEMIA, MYELOID, ACUTE; MAP KINASE SIGNALING SYSTEM; OXIDES; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; U937 CELLS;

EID: 84877846701     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.23760     Document Type: Article

References (48)

1. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010; 116:3751-7; PMID:20705755; http://dx.doi.org/10.1182/blood-2010-02-269621.
2. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19:3852-60; PMID:11559723.
3. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89:3354-60; PMID:9129042.
4. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94:3315-24; PMID:10552940.
5. Parmar S, Rundhaugen LM, Boehlke L, Riley M, Nabhan C, Raji A, et al. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk Res 2004; 28:909-19; PMID:15234567; http://dx.doi.org/10.1016/j. leukres. 2003.12.012.
6. Platanias LC. Biological responses to arsenic compounds. J Biol Chem 2009; 284:18583-7; PMID:19363033; http://dx.doi.org/10.1074/jbc. R900003200.
7. Goussetis DJ, Altman JK, Glaser H, McNeer JL, Tallman MS, Platanias LC. Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide. J Biol Chem 2010; 285:29989-97; PMID:20656687; http://dx.doi.org/10.1074/jbc. M109.090530.
8. Isakson P, Bjørås M, Bøe SO, Simonsen A. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood 2010; 116:2324-31; PMID:20574048; http://dx.doi.org/10.1182/blood-2010-01- 261040.
9. Goussetis DJ, Gounaris E, Wu EJ, Vakana E, Sharma B, Bogyo M, et al. Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. [Epub ahead of print]. Blood 2012; 120:3555-62; PMID:22898604; http://dx.doi.org/10.1182/blood-2012-01-402578.
10. Milella M, Precupanu CM, Gregorj C, Ricciardi MR, Petrucci MT, Kornblau SM, et al. Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des 2005; 11:2779-95; PMID:16101455; http://dx.doi.org/10. 2174/1381612054546842.
11. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93:3074-80; PMID:10216104.
12. Neubauer A, Dodge RK, George SL, Davey FR, Silver RT, Schiffer CA, et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 1994; 83:1603-11; PMID:8123851.
13. Lunghi P, Tabilio A, Dall'Aglio PP, Ridolo E, Carlo-Stella C, Pelicci PG, et al. Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia 2003; 17:1783-93; PMID:12970778; http://dx.doi.org/10.1038/sj.leu.2403032.
14. Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 2008; 9:747-58; PMID:18813292; http://dx.doi.org/10.1038/nrm2509.
15. Verma A, Mohindru M, Deb DK, Sassano A, Kambhampati S, Ravandi F, et al. Activation of Rac1 and the p38 mitogen-Activated protein kinase pathway in response to arsenic trioxide. J Biol Chem 2002; 277:44988-95; PMID:12239215; http://dx.doi.org/10.1074/jbc.M207176200.
16. Giafis N, Katsoulidis E, Sassano A, Tallman MS, Higgins LS, Nebreda AR, et al. Role of the p38 mitogen-Activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res 2006; 66:6763-71; PMID:16818652; http://dx.doi.org/10.1158/0008-5472.CAN-05-3699.
17. Dolniak B, Katsoulidis E, Carayol N, Altman JK, Redig AJ, Tallman MS, et al. Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2. J Biol Chem 2008; 283:12034-42; PMID:18299328; http://dx.doi.org/10.1074/jbc. M708816200.
18. Kannan-Thulasiraman P, Katsoulidis E, Tallman MS, Arthur JS, Platanias LC. Activation of the mitogenand stress-Activated kinase 1 by arsenic trioxide. J Biol Chem 2006; 281:22446-52; PMID:16762916; http://dx.doi.org/10.1074/jbc. M603111200.
19. McNeer JL, Goussetis DJ, Sassano A, Dolniak B, Kroczynska B, Glaser H, et al. Arsenic trioxide-dependent activation of thousand-And-one amino acid kinase 2 and transforming growth factor-beta-Activated kinase 1. Mol Pharmacol 2010; 77:828-35; PMID:20159944; http://dx.doi.org/10.1124/mol.109.061507.
20. Lunghi P, Giuliani N, Mazzera L, Lombardi G, Ricca M, Corradi A, et al. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood 2008; 112:2450-62; PMID:18583568; http://dx.doi.org/10.1182/blood-2007-10-114348.
21. Carriere A, Ray H, Blenis J, Roux PP. The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci 2008; 13:4258-75; PMID:18508509; http://dx.doi.org/10.2741/3003.
22. Altman JK, Yoon P, Katsoulidis E, Kroczynska B, Sassano A, Redig AJ, et al. Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. J Biol Chem 2008; 283:1992-2001; PMID:18048359; http://dx.doi.org/10.1074/jbc.M705227200.
23. Yoon P, Giafis N, Smith J, Mears H, Katsoulidis E, Sassano A, et al. Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. Mol Cancer Ther 2006; 5:2815-23; PMID:17121928; http://dx.doi.org/10.1158/1535-7163.MCT-06-0263.
24. Platanias LC. Biological responses to arsenic compounds. J Biol Chem 2009; 284:18583-7; PMID:19363033; http://dx.doi.org/10.1074/jbc. R900003200.
25. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010; 37:299-310; PMID:20159550; http://dx.doi.org/10.1016/j. molcel.2010.01.025.
26. Yang X, Liu L, Sternberg D, Tang L, Galinsky I, DeAngelo D, et al. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112. Cancer Res 2005; 65:7338-47; PMID:16103085; http://dx.doi.org/10.1158/0008-5472.CAN-04-2263.
27. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Bäsecke J, et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008; 22:708-22; PMID:18337766; http://dx.doi.org/10.1038/leu.2008.27.
28. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773:1263-84; PMID:17126425; http://dx.doi.org/10.1016/j.bbamcr.2006.10.001.
29. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Bäsecke J, et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008; 22:686-707; PMID:18337767; http://dx.doi.org/10.1038/leu.2008.26.
30. Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 2011; 25:1080-94; PMID:21494257; http://dx.doi.org/10.1038/leu.2011.66.
31. Chung E, Kondo M. Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development. Immunol Res 2011; 49:248-68; PMID:21170740; http://dx.doi.org/10.1007/s12026-010-8187-5.
32. Romeo Y, Zhang X, Roux PP. Regulation and function of the RSK family of protein kinases. Biochem J 2012; 441:553-69; PMID:22187936; http://dx.doi.org/ 10.1042/BJ20110289.
33. Elf S, Blevins D, Jin L, Chung TW, Williams IR, Lee BH, et al. p90RSK2 is essential for FLT3-ITD-but dispensable for BCR-ABL-induced myeloid leukemia. Blood 2011; 117:6885-94; PMID:21527514; http://dx.doi.org/10.1182/blood-2010-10- 315721.
34. Fujita N, Sato S, Tsuruo T. Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization. J Biol Chem 2003; 278:49254-60; PMID:14504289; http://dx.doi.org/10.1074/jbc. M306614200.
35. Zhu J, Blenis J, Yuan J. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A 2008; 105:6584-9; PMID:18451027; http://dx.doi.org/10.1073/pnas.0802785105.
36. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A 2004; 101:13489-94; PMID:15342917; http://dx.doi.org/10.1073/pnas.0405659101.
37. Carrière A, Cargnello M, Julien LA, Gao H, Bonneil E, Thibault P, et al. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol 2008; 18:1269-77; PMID:18722121; http://dx.doi.org/10.1016/j.cub.2008.07.078.
38. Hagner PR, Schneider A, Gartenhaus RB. Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood 2010; 115:2127-35; PMID:20075156; http://dx.doi.org/10.1182/blood-2009-09- 220020.
39. Redig AJ, Vakana E, Platanias LC. Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL. Leuk Lymphoma 2011; 52(Suppl 1):45-53; PMID:21299459; http://dx.doi.org/10.3109/ 10428194.2010.546919.
40. Beauchamp EM, Platanias LC. The evolution of the TOR pathway and its role in cancer. [Epub ahead of print]. Oncogene 2012; PMID:23246968; http://dx.doi.org/10.1038/onc.2012.567.
41. Uddin S, Yenush L, Sun XJ, Sweet ME, White MF, Platanias LC. Interferon-Alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3'-kinase. J Biol Chem 1995; 270:15938-41; PMID:7608146; http://dx.doi.org/10.1074/jbc.270.27.15938.
42. Verma A, Deb DK, Sassano A, Uddin S, Varga J, Wickrema A, et al. Activation of the p38 mitogenactivated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem 2002; 277:7726-35; PMID:11773065; http://dx.doi.org/10.1074/jbc.M106640200.
43. Mayer IA, Verma A, Grumbach IM, Uddin S, Lekmine F, Ravandi F, et al. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-Alpha in BCR-ABL-expressing cells. J Biol Chem 2001; 276:28570-7; PMID:11353767; http://dx.doi.org/10.1074/jbc.M011685200.
44. Sassano A, Katsoulidis E, Antico G, Altman JK, Redig AJ, Minucci S, et al. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 2007; 67:4524-32; PMID:17483369; http://dx.doi.org/10.1158/0008-5472.CAN- 06-3686.
45. Sassano A, Lo Iacono M, Antico G, Jordan A, Uddin S, Calogero RA, et al. Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins. Mol Cancer Ther 2009; 8:615-25; PMID:19240159; http://dx.doi.org/ 10.1158/1535-7163.MCT-08-1196.
46. Altman JK, Sassano A, Kaur S, Glaser H, Kroczynska B, Redig AJ, et al. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res 2011; 17:4378-88; PMID:21415215; http://dx.doi.org/10.1158/1078-0432.CCR-10-2285.
47. Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H, et al. Critical roles for mTORC2-And rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A 2010; 107:12469-74; PMID:20616057; http://dx.doi.org/10.1073/pnas.1005114107.
48. Vakana E, Altman JK, Glaser H, Donato NJ, Platanias LC. Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood 2011; 118:6399-402; PMID:22021366; http://dx.doi.org/10.1182/blood-2011-01-332783.